期刊文献+

国外脑卒中药物经济学研究概况 被引量:1

General Situation of Pharmacoeconomic Study on Stroke in Foreign Countries
原文传递
导出
摘要 目的:了解国外在脑卒中防治方面的药物经济学研究,为我国在相关领域开展药物经济学研究提供参考。方法:从脑卒中的预防、诊断、治疗、康复、护理及模型研究方法等方面,概述了国外药物经济学研究的进展。结果:国外注重对脑卒中二级预防的药物经济学研究,普遍采用模型研究方法,注重敏感性分析。结论:国外药物经济学研究方法和技术日益完善和成熟,为我国开展高质量的脑卒中药物经济学研究提供了借鉴。 OBJECTIVE: To analyze the research of foreign pharmacoeconomic study on prevention and treatment of stroke, and provide reference for pharmacoeconomic study in related fields in China. METHODS: The research progress of foreign pharmacoeconomic study was summarized from the stroke’s prevention, diagnosis, treatment, rehabilitation, nursing and model methods. RESULTS: Foreign countries focused on pharmacoeconomic study of secondary prevention for stroke, commonly adopted model methods, focused on sensitivity analysis. CONCLUSION: Foreign pharmacoeconomic research methods and techniques have become more perfect and mature, to provide a reference for high-quality pharmacoeconomic study on stroke in China.
出处 《中国药房》 CAS CSCD 2012年第46期4323-4326,共4页 China Pharmacy
基金 "863"课题:缺血性中风早期康复与避免复发的中医方案研究(2007AA02Z4B2) 国家自然科学基金课题:基于GLSISSM模型的缺血性中风复发高危因素早期预警新方法研究(81173472) 中医科学院自主选题:基于随访的缺血性中风复发高危因素风险模型的建立与中医康复技术依从性的实效研究(Z0191)
关键词 脑卒中 药物经济学 国外研究 Stroke Pharmacoeconomics Foreign study
  • 相关文献

参考文献34

  • 1胡善联.上市后药物的经济学评价[J].中国循证医学杂志,2005,5(5):353-356. 被引量:20
  • 2Sundberg G, Bagust A, Terent A. A model for costs of str- oke services[J].Health Policy, 2003,63 ( 1 ) : 81.
  • 3Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke preven- tion in atrial fibrillation[J].Ann Intern Med, 2011,154 ( 1 ) : 1.
  • 4Shah SV, Gage BF.Cost-effectiveness of dabigatran for st- roke prophylaxis in atrial fibrillation[J]. Circulation, 2011,123(22) :2 562.
  • 5Sorensen SV, Kansal AR, Connolly S, et al. Cost-effec- tiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Ca- nadian payer perspective[J].Thromb Haemostl 2011, 105 (5):908.
  • 6Kansal AR, Sorensen SV, Gani R, et al.Cost-effective- ness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrilla- tion[J]. Heart, 2012,98 (7) : 573.
  • 7Langkilde LK, Bergholdt Asmussen M, Overgaard M. Cost- effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clin- ical practice in Denmark[J]. J Med Econ, 2012, 15 (4) : 695.
  • 8Claes C, Mittendorf T, Grond M, et al. Incremental cost- effectiveness of dipyridamole + acetylsalicylic acid in sec- ondary prevention of ischemie noncardioembolic stroke [J].MedKlin (Munich), 2008,103 ( 11 ) : 778.
  • 9Marissal JP, Selke B.Economic assessment of the second- ary prevention of ischaemic stroke with dipyridamole plusaspirin (Aggrenox/Asasantin) in France[J].Pharmacoeco- nomics, 2004,22 (10) : 661.
  • 10Matchar DB, Samsa GP, Liu S. Cost-effectiveness of anti- platelet agents in secondary stroke prevention: the limits of certainty[J]. Value Health, 2005,8(5) : 572.

二级参考文献34

  • 1胡大一,杨进刚.应重视上市后药物安全性的循证医学再评价——罗非昔布召回的意义[J].中国循证医学杂志,2005,5(2):94-96. 被引量:3
  • 2陈文 胡善联.药物经济学研究[A].见:王龙兴主编.卫生经济学的理论与实践[C].上海:上海交通大学出版社,1998.230~ 247.
  • 3陈文.成本效果分析[A].见:胡善联主编.卫生经济学[C].上海:复旦大学出版社,2003.315~ 335.
  • 4许世斌 俞顺章 陈洁.上海市 2所医院鼻咽癌病例诊断治疗的成本-效果分析[J].中国卫生经济,1993,12(5):38-38.
  • 5JOSEPH L, MICHAEL D, DENNIS F, et al. Retaining and en- hancing the QALY [ J ]. Value Health, 2009, 12 ( sup 1 ) : 1-4, 18 -26.
  • 6HUFFORD M. Methodological advances in the assessment of quali- ty of life in clinical trials [J]. Value Health, 2008, 4(;2) : 181-182.
  • 7SCOTT R, RICHARD W, ANDREW B, et al. Good research practices tbr cost-effectiveness analysis ahongside clinical trials: the ISPOR RCT-CEA task force report [ J]. Value Health, 2005, 8 (5) : 521-534.
  • 8MILTON C W, BERNIE O B, JOHN H, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices-modeling studies[J]. Value Health, 2003, 6(1 ): 9-17.
  • 9KARNON J, GOYDER E, TAPPENDEN P, et al. A review and critique of modelling in prioritising and designing screening pro- grammes[J]. Health Technol Assess, 2007,11 (52) :Ⅲ-Ⅳ, Ⅸ-Ⅺ.
  • 10PELHAM B, STIRLING B, SUZANNE R. Modelling in the eco- nomic evaluation of heath care: selecting the appropriate ap- proach [J]. J Health Services Research & Policy, 2004,9(2) : 110-118.

共引文献69

同被引文献9

引证文献1

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部